Myasthenia gravis is an autoimmune disease where your immune system attacks the connection between your nerves and muscles, causing weakness that worsens with activity and improves with rest. It affects roughly 36 per 100,000 people in the United States, which translates to an estimated 116,000 Americans living with the condition.
How Nerve-to-Muscle Signals Break Down
Normally, when your brain tells a muscle to move, nerve endings release a chemical messenger called acetylcholine. That messenger crosses a tiny gap between the nerve and muscle (the neuromuscular junction), latches onto receptors on the muscle, and triggers a contraction. In myasthenia gravis, your immune system produces antibodies that block, alter, or destroy those receptors. With fewer working receptors, the signal weakens and the muscle can’t contract the way it should.
About 80% of people with generalized myasthenia gravis have antibodies targeting acetylcholine receptors directly. Another 10% have antibodies against a different protein called MuSK, which helps organize those receptors on the muscle surface. A smaller group tests positive for antibodies against yet another protein (LRP4), and some patients have no detectable antibodies at all, even though their symptoms are the same.
Who Gets Myasthenia Gravis
About 60% of patients are women. Women tend to develop the disease earlier, with a median age of 56, while the median age for men is 63. Before age 60, new cases are more common in women. After 60, the pattern flips: men are diagnosed at higher rates. This age-and-sex split is one of the more distinctive features of the disease’s demographics.
Symptoms: Eyes First, Then Beyond
More than three-quarters of people with myasthenia gravis first notice problems with their eyes. The most common early symptoms are a drooping eyelid (ptosis) and double vision (diplopia), both of which tend to fluctuate and worsen with sustained use. Some people’s symptoms stay confined to the eyes permanently. This is called ocular myasthenia gravis, and it accounts for about 20% of cases.
For the remaining 80%, the disease eventually spreads to other muscle groups. About half of people who start with eye symptoms develop generalized weakness within six months. By three years, roughly 90% who are going to generalize will have done so. Generalized myasthenia gravis can affect muscles in the face, neck, arms, legs, and, most critically, those involved in breathing and swallowing. Chewing might become exhausting partway through a meal. Speaking may grow slurred after a few minutes of conversation. The hallmark of all these symptoms is that they get worse with repeated use and improve after rest.
How It’s Diagnosed
A blood test for acetylcholine receptor antibodies is the most straightforward diagnostic tool and comes back positive in about 80% of people with generalized disease. If that test is negative, doctors check for MuSK antibodies, which account for another 10%. For the remaining patients who test negative for both, antibodies to LRP4 or agrin are sometimes found, though only about 15% of this “double-negative” group will test positive for those. Regardless of blood results, electrical tests that measure how well nerves communicate with muscles (repetitive nerve stimulation or single-fiber electromyography) can confirm the diagnosis even when antibodies aren’t detectable.
Treatment and Managing Symptoms
The first medication most people receive is pyridostigmine, which works by preventing the breakdown of acetylcholine at the neuromuscular junction. This means more of the chemical messenger sticks around to activate whatever receptors remain, improving muscle strength. The dose is adjusted based on how well symptoms respond.
If pyridostigmine alone isn’t enough to meet a patient’s goals, corticosteroids or other immune-suppressing medications are added. These drugs dial down the immune system’s attack on the neuromuscular junction. They take longer to work, sometimes weeks to months, and come with side effects from prolonged immune suppression, but for many people they’re necessary to control the disease.
A newer class of treatment became available in late 2021, when the FDA approved efgartigimod (sold as Vyvgart) for generalized myasthenia gravis with acetylcholine receptor antibodies. This drug works by lowering the overall level of antibodies in the blood, including the harmful ones causing the disease. It represents a more targeted approach than traditional immune suppression.
Thymectomy
The thymus gland, located behind the breastbone, plays a role in immune function and is sometimes abnormal in myasthenia gravis patients. Surgical removal of the thymus (thymectomy) has been shown in a major randomized trial published in the New England Journal of Medicine to improve outcomes over three years in patients without a thymus tumor. Those who had surgery needed lower doses of corticosteroids and had better symptom control. The benefits appeared consistent across age groups and sexes, though patients who had previously used corticosteroids seemed to gain the most. Not everyone is a candidate, and the decision depends on the specifics of each case.
Myasthenic Crisis
The most dangerous complication is myasthenic crisis, which occurs when breathing muscles become too weak to maintain adequate airflow. This is a medical emergency that requires intensive care and often mechanical ventilation. Respiratory failure is the leading cause of death during a crisis. In large population studies, myasthenic crisis occurs in roughly 5% of hospitalized patients, with mortality rates during crisis ranging from about 6% to higher figures depending on the healthcare setting and how quickly treatment begins. Common co-occurring problems during crisis include lung infections, electrolyte imbalances, and complications from other chronic conditions.
Life Expectancy and Long-Term Outlook
With modern treatment, many people with myasthenia gravis live close to a normal lifespan. Some studies, including one from Sweden, have found mortality rates comparable to the general population. Others paint a slightly different picture. An Israeli study found that men with myasthenia gravis died at an average age of 78.3 years compared to 81.6 in the general population, a statistically significant gap. For women, the difference was larger: 76.5 years versus 85.2 years expected. The gap was most pronounced at the extremes of age, with teenagers and those over 70 facing the highest relative risk.
These numbers reflect averages across all patients, including those with severe disease and significant complications. For individuals whose symptoms are well controlled with medication or surgery, the outlook is considerably better. The trajectory has improved dramatically over the past several decades, as mortality from myasthenic crisis has dropped sharply with advances in intensive care and immunotherapy.